REVIEW ON ANTIHYPERLIPEDEMIA LIPOPHILIC DRUGS AND THEIR NOVEL FORMULATION APPROACHES
It has been ranked as one of the greatest risk factors contributing to prevalence and severity of coronary heart diseases (CHD). CHD, stroke, atherosclerosis and hyperlipidemia are the primary cause of death. The increased levels of serum total cholesterol and low density lipoprotein (LDL) have been reported as a primary risk factor for cardiovascular disease. Hyperlipidemia is irregularly elevated levels of any or all lipids or lipoproteins in the blood i.e. fatty substances are found in the blood. Many drugs have been reported to inihibit the enzymes responsible for the synthesis of Cholesterol. Wherein, solubility is the key parameter for any active ingredient to maintain the desired therapeutic effects. Since various types of formulations are being currently prepared to enhance its solubility which in turn may improve the bioavailability of the drug? Studies reveal that different methodologies were carried out to overcome the bioavailability issue which is the key limiting factor. The present study focuses on the different types of novel formulation approaches of lipid soluble drug.
2. Dhaliya SA, Surya AS, Dawn VT, Betty C, Arun K, Sunil C. A review of hyperlipidemia and medicinal plants. IJAPS BMS 2013;2:219-37.
3. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997;23:3-25.
4. Shelke S, Shahi S, Jadhav K, Dhamecha D, Tiwari R, Patil H. Thermoreversible nano-ethosomal gel for the intranasal delivery of Eletriptan hydrobromide. J Mater Sci Mater Med 2016;27:1-3.
5. Shelke S, Shahi S, Jalalpure S, Dhamecha D. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nano liposomes: formulation, optimization, evaluation and permeation studies. â€ŽJ Liposome Res 2016;26:313-23.
6. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58:173-82.
7. Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 2013;40:195-211.
8. Rohilla A, Dagar N, Rohilla S, Dahiya A, Kushnoor A. Hyperlipidemiaâ€“a deadly pathological condition. Int J Curr Pharm Res 2012;4:15-8.
9. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7.
10. Rohilla AN, Dagar N, Rohilla S, Dahiya A, Kushnoor A. Hyperlipidemiaâ€”a deadly pathological condition. Int J Curr Pharm Res 2012;4:15-8.
11. Nakamura K, Miyoshi T, Yunoki K, Ito H. Postprandial hyperlipidemia as a potential residual risk factor. J Cardiol 2016;67:335-9.
12. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544.
13. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-53.
14. Havel RJ. Approach to the patient with hyperlipidemia. Med Clin North Am 1982;66:319-33.
15. Shattat GF. A review article on hyperlipidemia: types, treatments and new drug targets. Biomed Pharm J 2015;7:399-409.
16. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995;332:1491-8.
17. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: a meta-analysis. J Ethnopharmacol 2016;194:260-8.
18. Zhong J, Gong W, Lu L, Chen J, Lu Z, Li H, et al. Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-Î³, AMPK/Akt/mTOR signalling and autophagy. Int Immunopharmacol 2017;42:176-84.
19. Aarthy S, HARI BV, Devi DR. Current trends in simvastatin therapy for enhanced efficiency. Int J Pharma Bio Sci 2014;5:279-88.
20. Kyriakidis AV, Raitsiou B, Sakagianni A, Harisopoulou V, Pyrgioti M, Panagopoulou A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006;73:259-64.
21. Fodor JG, Frohlich JJ, Genest JJ, McPherson PR. Recommendations for the management and treatment of dyslipidemia report of the working group on hyper-cholesterolemia and other dyslipidemias. Can Med Assoc J 2000;162:1441-7.
22. Ullrich IH. Evaluation of a high-fiber diet in hyperlipidemia: a review. J Am Coll Nutr 1987;6:19-25.
23. Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009;136:4-16.
24. Onwe PE, Folawiyo MA, Anyigor-Ogah CS, Umahi G, Okorocha AE, Afoke AO. Hyperlipidemia: etiology and possible control. IOSR J Dental Med Sci 2015;14:93-100.
25. AlKhalifa K, Al Ansari A, Alsayed AR, Violato C. The impact of sleeve gastrectomy on hyperlipidemia: a systematic review. Int J Obes 2013;1-7. http://dx.doi.org/10.1155/2013/643530
26. Mathur M, Kusum Devi V. Potential of novel drug delivery strategies for the treatment of hyperlipidemia. J Drug Target 2016:1-1. http://dx.doi.org/10.3109/1061186X.2016.1172586
27. Shelke S, Shahi S, Jalalpure S, Dhamecha D, Shengule S. Formulation and evaluation of thermoreversible mucoadhesive in-situ gel for intranasal delivery of naratriptan hydrochloride. J Drug Delivery Sci Technol 2015;29:238-44.
28. Sinkula AA, Yalkowsky SH. The rationale for the design of biologically reversible drug derivatives: prodrugs. â€ŽJ Pharm Sci 1975;64:181-210.
29. Banerjee PS, Robinson JR. Novel drug delivery systems. Clin Pharmacokinet 1991;20:1-4.
30. Punitha S, Kumar KS. Statin therapy and their formulation approaches: a review. Int J Pharm Sci 2011;3:23-6.
31. Aarthy S, Hari BV, Devi DR. Current trends in simvastatin therapy for enhanced efficiency. â€ŽInt J Pharma Bio Sci 2014;5:279-88.
32. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992;9:87-93.
33. Kaur J, Aggarwal G, Singh G, Rana AC. Improvement of drug solubility using solid dispersion. Int J Pharm Pharm Sci 2012;4:47-53.
34. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as a strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today 2007;12:1068-75.
35. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58:173-82.
36. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Grozdanis MT, Lenhardt T, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Delivery Rev 2007;59:419-26.
37. Lakshmi P, Kumar GA. Nanosuspension technology: a review. Int J Pharm Pharm Sci 2010 2:35-40.
38. Glueck CJ, Ford S, Scheel D, Steiner P. Colestipol and cholestyramine resin: comparative effects in familial type II hyperlipoproteinemia. JAMA 1972;222:676-81.
39. Anand V, Kandarapu R, Garg S. Ion-exchange resins: carrying drug delivery forward. Drug Discovery Today 2001;6:905-14.
40. Mathur M, Kusum Devi V. Potential of novel drug delivery strategies for the treatment of hyperlipidemia. â€ŽJ Drug Target 2016;24:916-26.
41. Yedurkar P, Dhiman MK, Petkar K, Sawant K. Biopolymeric mucoadhesive bilayer patch of pravastatin sodium for Buccal delivery and treatment of patients with atherosclerosis. Drug Dev Ind Pharm 2013;39:670-80.
42. Dhiman S, Singh TG, Rehni AK, Sood S, Arora S. Gastroretentive: a controlled release drug delivery system. Asian J Pharm Clin Res 2011;4:5-13.
43. Kumar K, Shah MH, Ketkar A, Mahadik KR, Paradkar A. Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices. Int J Pharm 2004;272:151-60.
44. Benita S. editor. Microencapsulation: methods and industrial applications. CRC Press; 2005.
45. Sharma S, Pawar A. Low-density multi particulate system for pulsatile release of meloxicam. Int J Pharm 2006;313:150-8.
46. Mishra RK, Banthia AK, Majeed AB. Pectin based formulations for biomedical applications: a review. Asian J Pharm Clin Res. 2012;5:1-7.
47. Shelke S, Shahi S, Kale S, Patil V, Deshpande D. Ethosomes: a novel deformable carrier. World J Pharm Sci 2015;9;1830-9.
48. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Delivery Rev 2007;59:677-94.
49. Kumar PT, Mishra J, Podder A. Design, fabrication and evaluation of rosuvastatin Pharmac some-a novel sustained release drug delivery syste. Eur J Pharm Med Res 2016;3:332-50.
50. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with the solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62-76.
51. Punitha S, KUMAR KS. Statin therapy and their formulation approaches a review. Int J Pharm Pharm Sci 2011;3:41-4.
52. Singh BB, Vinjamury SP, Der-Martirosian C, Kubik E. Ayurvedic and collateral herbal treatments for hyperlipidemia: a systematic review of randomized controlled trials and quasi-experimental designs. Alternative Ther Health Med 2007;13:22.
53. Kaushik V, Saini V. Hyperlipidemia: its management and induction. Int J Pharm Sci Res 2014;5:3152.